A groundbreaking discovery from the Weizmann Institute of Science is turning heads in the health and wellness world: researchers have identified a protein called MTCH2 — nicknamed “Mitch” — that acts as a master switch controlling whether human cells burn fat or store it. Published on October 24, 2026, the findings raise exciting new possibilities for obesity treatment that go far beyond appetite suppression.
When scientists disabled the Mitch protein in human cell experiments, those cells dramatically increased their consumption of fats, carbohydrates, and amino acids for energy — and, crucially, had a much harder time forming new fat cells. The mechanism works through mitochondria: removing Mitch fragments the mitochondrial network, forcing cells into a less efficient energy mode that burns through significantly more fuel, much of it derived from fat.
Earlier experiments in mice showed equally remarkable results. Animals without Mitch in their muscle tissue became leaner, developed greater endurance, gained more muscle fibers, and proved highly resistant to obesity. This is particularly significant because popular weight-loss drugs such as GLP-1 agonists (like Ozempic and Wegovy) often cause unwanted muscle loss alongside fat loss — a drawback that targeting Mitch could potentially sidestep.
The study, published in the EMBO Journal and led by Professor Atan Gross and doctoral student Sabita Chourasia, represents a new frontier in metabolic science. While human clinical trials are still needed, experts say the discovery opens a fundamentally new path to fighting obesity by changing how the body’s cells use energy rather than simply reducing caloric intake.
Source: ScienceDaily – Weizmann Institute of Science, October 24, 2026